Recipharm AB has entered into an agreement to acquire a majority stake in Nitin Lifesciences Ltd., an Indian sterile injectables CMO, currently owned by the Sobti family. Recipharm will acquire 74% of the shares for an estimated purchase consideration of $105.4 million, and will join forces with the founding and managing owners to further grow the current business.   The combined companies will have enhanced scale, reach and profitability with current pro-forma revenue of $423 million (+13 %)....